Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

2.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

3.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

4.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.

5.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ.

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. No abstract available.

6.

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.

Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.

Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):625-636.e3. doi: 10.1016/j.clml.2016.08.006. Epub 2016 Aug 10.

7.

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O.

Invest New Drugs. 2016 Aug;34(4):439-49. doi: 10.1007/s10637-016-0348-5. Epub 2016 Apr 8.

8.

Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.

Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambinder R, Baiocchi R, Dezube BJ, Henry D, Kaplan L, Levine AM, Mitsuyasu R, Ratner L, Reid E, Remick S, Sparano J, Tzachanis D, Wachsman W, Chadburn A.

Leuk Lymphoma. 2016 Jul;57(7):1731-4. doi: 10.3109/10428194.2015.1113281. Epub 2015 Dec 16. No abstract available.

9.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S.

Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

10.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

11.

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC.

Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2. Erratum in: Br J Haematol. 2015 Oct;171(2):294. Br J Haematol. 2015 Oct;171(2):294.

12.

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J.

Cancer Immunol Immunother. 2015 Apr;64(4):437-46. doi: 10.1007/s00262-015-1653-0. Epub 2015 Jan 13.

PMID:
25579378
13.

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.

Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, Mahadevan D.

Clin Cancer Res. 2015 Jan 1;21(1):87-97. doi: 10.1158/1078-0432.CCR-14-0979. Epub 2014 Oct 21.

14.

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP.

PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.

15.

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.

16.

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A.

J Clin Oncol. 2014 Feb 10;32(5):402-8. doi: 10.1200/JCO.2012.48.6365. Epub 2013 Dec 30.

17.

Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium.

Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE.

Genes Cancer. 2012 Jul;3(7-8):512-20. doi: 10.1177/1947601912466556.

18.

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A.

J Clin Oncol. 2013 Jan 1;31(1):58-64. doi: 10.1200/JCO.2012.42.4648. Epub 2012 Nov 19.

19.

Fine needle aspiration of salivary gland masses in HIV-infected patients.

Michelow P, Dezube BJ, Pantanowitz L.

Diagn Cytopathol. 2012 Aug;40(8):684-90. doi: 10.1002/dc.21597. Epub 2011 Jan 6.

PMID:
22807383
20.

The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ.

Clin Infect Dis. 2012 Nov;55(9):1228-35. doi: 10.1093/cid/cis613. Epub 2012 Jul 9. Review.

21.

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ.

Clin Cancer Res. 2012 Jun 15;18(12):3396-406. doi: 10.1158/1078-0432.CCR-11-2703. Epub 2012 May 25.

22.

Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.

Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkataramanan R, Han K, Cesarman E, Dittmer DP.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):447-54. doi: 10.1097/QAI.0b013e31823e7884.

23.

Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies.

Ramos JC, Sin SH, Staudt MR, Roy D, Vahrson W, Dezube BJ, Harrington W Jr, Dittmer DP.

Int J Cancer. 2012 Jun 1;130(11):2728-33. doi: 10.1002/ijc.26302. Epub 2011 Aug 29.

24.

Personalized medicine for acute myelogenous leukemia--at the entrance gate.

Swords RT, Dezube BJ, Medeiros BC.

Am J Hematol. 2011 Aug;86(8):631-2. doi: 10.1002/ajh.22060. No abstract available.

25.

Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.

Cianfrocca M, Lee S, Von Roenn J, Rudek MA, Dezube BJ, Krown SE, Sparano JA.

Cancer Chemother Pharmacol. 2011 Oct;68(4):827-33. doi: 10.1007/s00280-010-1509-4. Epub 2011 Jan 5.

26.

Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.

27.

Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration.

D'Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM.

Clin Lung Cancer. 2010 Nov 1;11(6):396-404. doi: 10.3816/CLC.2010.n.051.

PMID:
21062730
28.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.

N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

29.

Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.

Richards C, Pantanowitz L, Dezube BJ.

Pharmacol Res. 2011 Feb;63(2):151-6. doi: 10.1016/j.phrs.2010.10.008. Epub 2010 Oct 15. Review.

PMID:
20951804
30.

Time for oncologists to opt in for routine opt-out HIV testing?

Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, Mitsuyasu R, Pantanowitz L.

JAMA. 2010 Jul 21;304(3):334-9. doi: 10.1001/jama.2010.752.

31.

Fine needle aspiration of breast masses in HIV-infected patients: results from a large series.

Michelow P, Dezube BJ, Pantanowitz L.

Cancer Cytopathol. 2010 Aug 25;118(4):218-24. doi: 10.1002/cncy.20083.

32.

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.

Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA.

Cancer. 2010 Aug 15;116(16):3969-77. doi: 10.1002/cncr.25362.

33.

Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men.

Schlecht HP, Fugelso DK, Murphy RK, Wagner KT, Doweiko JP, Proper J, Dezube BJ, Panther LA.

Clin Infect Dis. 2010 Jul 1;51(1):107-10. doi: 10.1086/653426.

34.

AIDS-related Kaposi's sarcoma of the gastrointestinal tract.

Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR.

J Clin Oncol. 2010 Jun 1;28(16):e250-1. doi: 10.1200/JCO.2009.26.5868. Epub 2010 May 3. No abstract available.

PMID:
20439636
35.

Letter: Kaposi sarcoma versus nephrogenic systemic fibrosis.

Pantanowitz L, Dezube BJ.

Dermatol Online J. 2010 Mar 15;16(3):13.

36.

Human Immunodeficiency Virus-associated anaplastic large cell lymphoma.

Perez K, Castillo J, Dezube BJ, Pantanowitz L.

Leuk Lymphoma. 2010 Mar;51(3):430-8. doi: 10.3109/10428190903572201. Review.

PMID:
20141444
37.

Primary esophageal carcinoma in the era of highly active antiretroviral therapy.

Stebbing J, Krown SE, Bower M, Batra A, Slater S, Serraino D, Dezube BJ, Dhir AA, Pantanowitz L.

Arch Intern Med. 2010 Jan 25;170(2):203-7. doi: 10.1001/archinternmed.2009.490.

PMID:
20101017
38.

Monocytes tied to HIV-associated thrombosis.

Pantanowitz L, Dezube BJ.

Blood. 2010 Jan 14;115(2):156-7. doi: 10.1182/blood-2009-11-250597. No abstract available.

39.

Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation.

Douglas JL, Gustin JK, Moses AV, Dezube BJ, Pantanowitz L.

Transl Biomed. 2010;1(2). pii: 172.

40.

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium.

Blood. 2010 Apr 15;115(15):3008-16. doi: 10.1182/blood-2009-08-231613. Epub 2009 Dec 18.

41.

The anal Pap test as a screening tool.

Pantanowitz L, Dezube BJ.

AIDS. 2010 Jan 28;24(3):463-5. doi: 10.1097/QAD.0b013e3283349b3c. No abstract available.

PMID:
19926960
42.

Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.

Lechowicz M, Dittmer DP, Lee JY, Krown SE, Wachsman W, Aboulafia D, Dezube BJ, Ratner L, Said J, Ambinder RF.

Clin Infect Dis. 2009 Dec 15;49(12):1946-9. doi: 10.1086/648447.

43.

Human immunodeficiency virus-associated lung carcinoma presenting as cutaneous metastases.

Hamdan A, Dezube BJ, Pantanowitz L.

Clin Lung Cancer. 2009 Nov;10(6):441-4. doi: 10.3816/CLC.2009.n.083.

PMID:
19900864
44.

Immunohistochemistry in Kaposi's sarcoma.

Pantanowitz L, Otis CN, Dezube BJ.

Clin Exp Dermatol. 2010 Jan;35(1):68-72. doi: 10.1111/j.1365-2230.2009.03707.x. Epub 2009 Oct 23. Review.

PMID:
19874352
45.

Pathology of Kaposi's sarcoma.

Pantanowitz L, Grayson W, Simonart T, Dezube BJ.

J HIV Ther. 2009 Jun;14(2):41-7. Review. No abstract available.

PMID:
19839366
46.

Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review.

Castillo J, Perez K, Milani C, Dezube BJ, Pantanowitz L.

J HIV Ther. 2009 Jun;14(2):34-40. Review. No abstract available.

PMID:
19839365
47.

Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation.

Pantanowitz L, Pihan G, Carbone A, Dezube BJ.

J HIV Ther. 2009 Jun;14(2):24-33. Review. No abstract available.

PMID:
19839364
48.

Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome.

Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L.

Clin Colorectal Cancer. 2009 Oct;8(4):215-9. doi: 10.3816/CCC.2009.n.036.

PMID:
19822512
49.

Studying Rac1-induced tumorigenesis suggests antioxidants may help prevent and treat Kaposi's sarcoma.

Sullivan RJ, Pantanowitz L, Dezube BJ.

Future Oncol. 2009 Sep;5(7):949-52. doi: 10.2217/fon.09.83. No abstract available.

PMID:
19792964
50.

HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.

Gaughan EM, Dezube BJ, Bower M, Aboulafia DM, Bohac G, Cooley TP, Pantanowitz L.

BMC Urol. 2009 Aug 31;9:10. doi: 10.1186/1471-2490-9-10. Review.

Supplemental Content

Loading ...
Support Center